Last update :
18/04/2024
Anticancer drug   Vincristine sulfate  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Cellecristin Germany
Citomid Chile, Colombia, Mexico, Peru
Crisovin Colombia, Ecuador, Mexico
Cytocristin Malaysia
DBL vincristine sulfate Malaysia, New Zealand
Farmistin Germany
Marqibo United States of America
Nefixol Mexico
Oncocristin Colombia
Oncovin Austria, Colombia, Denmark, Finland, France, Great Britain, Luxembourg, Mexico, Morocco, Saudi Arabia, Sweden, Switzerland, United Arab Emirates
Onkocristin Germany
Sindovin Iran
Sulfato de vincristine Venezuela
Unicristin Peru
Vinblax Mexico
Vincasar Mexico, United States of America
Vincrisin Belgium
Vincristin Austria, Germany, Hungary, Switzerland
Vincristina Argentina, Chile, Colombia, Ecuador, Iceland, Iran, Italy, Peru, Spain, Venezuela
Vincristine France, Greece, Luxembourg, Malaysia, Morocco, Norway, Sweden, Switzerland, Tunisia, Turkey
Vincristine sulfat Turkey
Vincristine sulfate Canada, United States of America
Vincristine sulphate Egypt, Great Britain, Ireland, Malaysia, New Zealand, Poland, United Arab Emirates
Vincristinesulfaat Netherlands
Vincristinum Luxembourg
Vincrisul Spain
Vinlon Lyo Peru
Vinracine Egypt, Malaysia
Vintec Mexico
Stability in solutions   Injection   Stability in solutions : Vincristine sulfate     
Container Solvent Concentration Temperature Storage Duration of stability References
Glass Water for Injection 1 mg/ml 4°C Protect from light
21 Day
481
Level of evidence B

Polyvinyl chloride NaCl 0,9% or Glucose 5% 0,02 mg/ml 4°C Protect from light
7 Day
144
Level of evidence D

Polyvinyl chloride Sodium chloride 0,9% 0,01>>0,12 mg/ml 4°C Protect from light
7 Day
1602
Level of evidence A+

Polyethylene NaCl 0,9% or Glucose 5% 0,001 & 0,02 mg/ml 25°C Protect from light
7 Day
1520
Manufacturer's stability data

Polypropylene NaCl 0,9% or Glucose 5% 0,02 mg/ml 25°C Protect from light
21 Day
481
Level of evidence B

Polypropylene NaCl 0,9% or Glucose 5% 0,02 mg/ml 4°C Protect from light
21 Day
481
Level of evidence B

Polypropylene Sodium chloride 0,9% 0,033 >> 0,121 mg/ml 25°C Protect from light
7 Day
3119
Level of evidence A

Polypropylene Sodium chloride 0,9% 0,033 >> 0,121 mg/ml 4°C Protect from light
7 Day
3119
Level of evidence A

Polypropylene Ringer’s lactate solution 0,02 mg/ml 25°C Protect from light
21 Day
481
Level of evidence B

Polypropylene Ringer’s lactate solution 0,02 mg/ml 4°C Protect from light
21 Day
481
Level of evidence B

Polyolefine Sodium chloride 0,9% 0,05 mg/ml 2-8°C Protect from light
84 Day
3214
Level of evidence A+

Polyolefine Sodium chloride 0,9% 0,05 mg/ml 25°C Protect from light
84 Day
3214
Level of evidence A+

Polypropylen Syringe Sodium chloride 0,9% 0,025 mg/ml 2-8°C Protect from light
84 Day
3214
Level of evidence A+

Polypropylen Syringe Sodium chloride 0,9% 0,025 mg/ml 25°C Protect from light
84 Day
3214
Level of evidence A+

Polypropylen Syringe Sodium chloride 0,9% 0,025>>0,15 mg/ml 4°C Protect from light
7 Day
1602
Level of evidence A+

Polypropylen Syringe Sodium chloride 0,9% 0,1 mg/ml 2-8°C Protect from light
84 Day
3214
Level of evidence A+

Polypropylen Syringe Sodium chloride 0,9% 0,1 mg/ml 25°C Protect from light
84 Day
3214
Level of evidence A+


  Mentions Légales